FSSAI Restricts Ashwagandha Leaf Use in Supplements Over Safety Concerns

India’s apex food regulator, Food Safety and Standards Authority of India, has tightened regulations around the use of ashwagandha in health supplements. Citing safety risks, the authority has prohibited the use of ashwagandha leaves and their extracts, allowing only the root and root-based derivatives in nutraceutical products.

New Directive Targets Ashwagandha Leaf Usage

In a recent regulatory update, FSSAI has explicitly barred manufacturers from using ashwagandha leaves in food supplements and wellness products. The directive aims to bring clarity and stricter compliance in the rapidly growing nutraceutical sector.

The regulator has instructed state authorities to:

• Monitor the use of ashwagandha in products
• Take legal action against violations
• Ensure proper labeling of plant parts used

This move comes amid increasing scrutiny of herbal ingredients being widely used in dietary supplements.

Only Roots Permitted for Consumption

FSSAI has clarified that only the roots of Ashwagandha and their extracts are approved for use in health and wellness products.

This clarification aligns with recommendations from the Ministry of Ayush, which has long advocated for the use of traditional plant parts backed by Ayurvedic practices.

Manufacturers are now required to:

• Clearly mention the plant part used on product labels
• Avoid using non-approved components such as leaves
• Adhere strictly to regulatory standards

Failure to comply could result in penalties under the Food Safety and Standards Act 2006.

Scientific Concerns Behind the Ban

The restriction stems from scientific findings highlighting potential health risks associated with ashwagandha leaves.

Studies cited in regulatory discussions indicate that leaves contain higher concentrations of reactive compounds known as withanolides—particularly withaferin-A.

These compounds may lead to:

• Liver toxicity
• Gastrointestinal discomfort
• Possible neurotoxic effects

Such findings prompted authorities to take a precautionary approach, prioritizing consumer safety over widespread commercial use.

Booming Global Demand for Ashwagandha

Ashwagandha has emerged as one of the most popular herbal ingredients worldwide, especially in the wellness and nutraceutical industries.

The global market for ashwagandha is projected to reach approximately $928.5 million by 2026, while the broader nutraceutical market is expected to grow from $38.77 billion to nearly $84.99 billion by 2033.

In international markets like North America and Europe, ashwagandha is widely marketed as an adaptogen—a natural substance believed to help the body manage stress.

It is commonly available in forms such as:

• Capsules and tablets
• Gummies and powders
• Herbal teas
• Functional beverages

Popularity in the Indian Market

In India, ashwagandha products are heavily marketed for their perceived health benefits, particularly among men.

These benefits include:

• Improved strength and stamina
• Enhanced energy levels
• Support for sexual wellness
• Potential boost in testosterone levels

However, the new regulatory move may reshape how these products are formulated and marketed in the country.

Strict Enforcement and Compliance Measures

FSSAI has issued clear instructions to state authorities to enforce the new rules rigorously.

Key enforcement measures include:

• Regular inspections of manufacturing units
• Verification of product ingredients
• Legal action against non-compliant businesses

The regulator has also emphasized the importance of transparency in labeling, ensuring that consumers are fully informed about the ingredients in their supplements.

Impact on Industry Players

The directive is expected to impact several major companies operating in the herbal and wellness space.

Prominent brands offering ashwagandha-based products include:

• Himalaya Wellness
• Dabur India
• Patanjali Ayurved
• Baidyanath
• Zandu

These companies may need to review their product formulations, supply chains, and labeling practices to ensure compliance with the updated guidelines.

Agricultural and Supply Chain Considerations

Ashwagandha cultivation is widespread across several Indian states, including:

• Madhya Pradesh
• Rajasthan
• Gujarat
• Maharashtra
• Uttar Pradesh
• Punjab
• Haryana

The crop is grown over an estimated 10,780 hectares, supporting thousands of farmers and contributing to rural economies.

The restriction on leaf usage could influence:

• Demand for specific plant parts
• Pricing dynamics in the supply chain
• Farming practices and harvesting methods

Farmers may now focus more on root cultivation to align with regulatory requirements.

Balancing Growth and Safety in Nutraceuticals

India’s nutraceutical industry is experiencing rapid growth, driven by rising health awareness and demand for natural remedies.

However, this expansion also raises concerns about:

• Product safety
• Standardization of ingredients
• Regulatory oversight

FSSAI’s move reflects an effort to strike a balance between promoting industry growth and ensuring consumer protection.

Global Implications and Market Adjustments

The decision could have ripple effects beyond India, as global companies sourcing ashwagandha may need to reconsider their formulations.

International markets, particularly in North America and Europe, may also face increased scrutiny regarding the safety of herbal ingredients.

This could lead to:

• Greater emphasis on scientific validation
• Stricter regulatory frameworks
• Increased consumer awareness

Conclusion

The FSSAI’s decision to ban the use of ashwagandha leaves in supplements marks a significant step toward strengthening regulatory oversight in India’s wellness industry. While the move may pose short-term challenges for manufacturers, it reinforces the importance of safety, transparency, and adherence to traditional knowledge.

As the nutraceutical market continues to expand, such measures are essential to building consumer trust and ensuring sustainable growth. By prioritizing scientifically validated practices, India aims to position itself as a responsible leader in the global herbal and wellness sector.